Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Radhwan Nidal Al-Zidan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Molecular mechanisms and regulation of inflammasome activation and signaling: sensing of pathogens and damage molecular patterns

    byĀ Sagar R. Dubey, Cynthia Turnbull, Abhimanu Pandey, Anyang Zhao, Melan Kurera, Radhwan Al-Zidan, Cheng Shen, Manjul Gautam, Shreya Mahajan, Poonam S. Jadhav, et al.

    The inflammasome is an inflammatory signaling protein complex comprising a sensor protein, the adaptor protein ASC, and the cysteine protease caspase-1. Inflammasome sensor proteins are activated by microbial molecular patterns, endogenous self-derived damage signals, or exogenous environmental danger signals. Multiple inflammasomes that differ in their mechanisms of action and structural composition have been identified. The best characterized are the canonical NLRP1, NLRP3, NAIP-NLRC4, AIM2, and Pyrin inflammasomes and the noncanonical inflammasomes activated by caspase-4, caspase-5 or caspase-11. The lesser known inflammasomes are the NLRP6, NLRP7, NLRP9, NLRP10, NLRP12, CARD8, and MxA inflammasomes. Following inflammasome assembly, caspase-1 promotes the secretion of the proinflammatory cytokines IL-1β and IL-18, and pyroptosis is mediated by the membrane-disrupting proteins gasdermin D and ninjurin-1. These functional activities control innate and adaptive immune responses and the initiation, development, and progression of autoinflammation, cancer, infectious diseases, and neurodegenerative diseases. Understanding how inflammasomes respond to pathogens and sterile signals has refined our view of innate immunity and offered new therapeutic targets. In this review, we present a comprehensive overview of inflammasomes with an emphasis on the mechanistic principles that govern inflammasome formation. We also discuss the contributions of inflammasome activation to health and disease.


  • Open Access

    Knowledge, Attitudes, and Practices of Iraqi Parents Regarding Antibiotic Use in Children and the Implications

    byĀ Omeed Darweesh, Amanj Kurdi, Marwan Merkhan, Hemn Ahmed, Salih Ibrahem, Radhwan N. Al-Zidan, Johanna C. Meyer, Brian Godman

    Background: Antibiotic misuse is a major global health issue, particularly in low- and middle-income countries (LMICs), where inappropriate use contributes to antimicrobial resistance (AMR). Inappropriate antibiotic use is exacerbated in LMICs by pressure from parents on physicians and pharmacists to prescribe and dispense antibiotics for their children, often for viral infections. There is currently limited knowledge of key issues in Iraq to improve future antibiotic use. Consequently, we explored knowledge, attitudes, and practices (KAPs) of Iraqi parents regarding antibiotic use in their children to provide future direction. Methods: A cross-sectional survey was conducted between November 2023 and September 2024 among 1878 parents in four districts of Iraq. A structured questionnaire assessed parents’ KAPs towards antibiotic-related uses and practices. Data were analyzed using descriptive statistics and Chi-square tests to examine the associations between demographic variables and KAP indicators. Results: Among the participants, 83% were aware that antibiotics are ineffective for viral infections, and 75% recognized potential side effects from antibiotics. Despite this knowledge, 63% of parents admitted to administering antibiotics to their children without a prescription, with 42% discontinuing treatment once symptoms improved. Factors including cost, dosage, and taste influenced antibiotic selection. Parents with higher education and income levels were more likely to engage in self-medication. Pharmacists were the primary source of antibiotic information for 52% of respondents. Conclusions: Despite adequate knowledge, inappropriate practices such as self-medication and discontinuing treatment early were prevalent. Targeted educational campaigns, particularly among parents with higher education levels and incomes, are necessary to mitigate AMR in Iraq.


  • Evaluation of the Pharmacologic Treatment of COVID-19 Pandemic in Iraq

    byĀ Omeed Darweesh, Ghayth M. Abdulrazzaq, Radhwan N. Al-Zidan, Pshtiwan Bebane, Marwan Merkhan, Ruya Aldabbagh, Nohad AlOmari

    The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or COVID-19) has been detrimental to human health, economy, and wellbeing. Little information is known on the epidemiology and outcome of the disease in a localized community within Iraq. We carried out an audit of confirmed cases of COVID-19 in the Kirkuk General Hospital. Data from the 20th of June to the 31st of July, 2020, were collected and analyzed. Suspected COVID-19 cases were confirmed by real-time polymerase chain reaction (RT-PCR). Data on clinical symptoms, age, and treatment protocols were analyzed concerning the outcome. Our study included a total of 200 individual confirmed COVID-19 patients. The majority of cases 55% (n = 110) displayed severe symptoms, while 32.5% (65 cases) and 12.5% (25 cases) of patients displayed moderate to mild symptoms, respectively. The rate of death in the referred patients was 5%. Most patients admitted to the hospital for treatment recovered and were discharged from the hospital within 5 to 30 days post-diagnosis. Statistical analysis revealed that patients treated with oseltamivir, hydroxychloroquine, and azithromycin in combination with vitamins C and D have shorter hospital stay compared to patients receiving the same therapeutic protocol in combination with steroids. Moreover, a higher mortality rate (4.5%) was observed in patients treated with oseltamivir, hydroxychloroquine, ceftriaxone, and steroids. This study highlights a significant relationship between age, secondary ailments, and the choice of medications as simple predictors of the outcome of COVID-19.


  • Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?

    byĀ Myasar Alkotaji, Radhwan N. Al-Zidan

    COVID-19 represents the biggest health challenge. Although the mortality rate of COVID-19 is low, the high numbers of infected people and those with post-COVID-19 symptoms represent a real problem for the health system. A high number of patients with COVID-19 or people recovered from COVID-19 suffer from a dry cough and/or myalgia. Interestingly, an imbalance in bradykinin was observed in COVID-19 patients, which might be due to the accumulation of bradykinin as a result of a reduction in the degradation of bradykinin. This finding inspired the idea of possible similitude between the dry cough that is induced by angiotensin-converting enzyme inhibitors and the COVID-19-induced dry cough. Both of these types of cough are mediated, at least partially, by bradykinin. They both manifested as a persistent dry cough that is not responded to traditional dry cough remedies. However, several drugs were previously investigated for the treatment of angiotensin-converting enzyme inhibitor–induced dry cough. Here, we hypothesized that such treatment might be useful in COVID-19-induced dry cough and other bradykinin-related symptoms such as generalized pain and myalgia. In this article, evidence was presented to support the use of indomethacin as a potential treatment of COVID-19-induced dry cough. The choice of indomethacin was based on its ability to suppress the cyclooxygenase enzyme while also lowering the level of the inflammatory mediator bradykinin. Furthermore, indomethacin has been shown to be effective in treating angiotensin-converting enzyme inhibitor–induced dry cough. Moreover, indomethacin is a long-established, low-cost, effective, and readily available medication.


  • Open Access

    High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases

    byĀ Hasan Aldewachi, Radhwan N. Al-Zidan, Matthew T. Conner, Mootaz M. Salman

    Neurodegenerative diseases (NDDs) are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells in the central nervous system (CNS). Identification of viable therapeutic targets and new treatments for CNS disorders and in particular, for NDDs is a major challenge in the field of drug discovery. These difficulties can be attributed to the diversity of cells involved, extreme complexity of the neural circuits, the limited capacity for tissue regeneration, and our incomplete understanding of the underlying pathological processes. Drug discovery is a complex and multidisciplinary process. The screening attrition rate in current drug discovery protocols mean that only one viable drug may arise from millions of screened compounds resulting in the need to improve discovery technologies and protocols to address the multiple causes of attrition. This has identified the need to screen larger libraries where the use of efficient high-throughput screening (HTS) becomes key in the discovery process. HTS can investigate hundreds of thousands of compounds per day. However, if fewer compounds could be screened without compromising the probability of success, the cost and time would be largely reduced. To that end, recent advances in computer-aided design, in silico libraries, and molecular docking software combined with the upscaling of cell-based platforms have evolved to improve screening efficiency with higher predictability and clinical applicability. We review, here, the increasing role of HTS in contemporary drug discovery processes, in particular for NDDs, and evaluate the criteria underlying its successful application. We also discuss the requirement of HTS for novel NDD therapies and examine the major current challenges in validating new drug targets and developing new treatments for NDDs.


  • Quality control study on conventional metronidazole tablets available in the Iraqi market

    byĀ Saad M. Majeed, K. Al-Shaheen, Radhwan N. Al-Zidan

    In the developing countries, particularly in Iraq, importing drugs from substandard manufacturers and smuggling of counterfeit medicines has become a major challenge to the healthcare services. Therefore, continuous post-marketing quality testing is necessary to verify the quality and determine which product could safely replace the innovator product in case of unavailability or the high cost of the innovator brand one. In the Iraqi market, Metronidazole tablets are available from different pharmaceutical companies. Metronidazole has been chosen for this comparative study because it is the most commonly prescribed antiprotozoal drug in Iraq and many other countries around the world. In this study, various quality control tests have been executed to determine the Pharmaceutical Equivalence of the various generic brands of Metronidazole film-coated tablets (500 mg) marketed in Iraq. The results of our study indicated that each of the tested brands has a unique pattern of in-vitro release profile concerning the (C10 min. and Tmax.), however, all the tested brands were in compliance with the USP specifications for the immediate release dosage forms. Also, there were considerable variations regarding the tablet weight, hardness, and disintegration time in comparison to the innovator brand, (Flagyl) Ā®. Moreover, there was a slight variance in content uniformity between the different brands. To conclude, brands MT-E and MT-C showed highest drug release at the required time interval with good quality as reflected by high values of the similarity factor (F2) and the physicochemical evaluation of the pharmaceutical parameters. Accordingly, brands MT-E and MT-C are pharmaceutically equivalent and can be used as an effective alternative to the innovator drug (Flagyl) Ā®.


  • Open Access

    Potential Drug-Drug and Drug-Disease interactions of selected experimental therapies used in treating COVID-19 patients

    byĀ Radhwan Nidal Al-Zidan

    At the end of 2019, the whole world was witnessing the birth of a new member of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) family in Wuhan city, China. Since then, the 2019 novel coronavirus (COVID-19) has rapidly invaded every corner of the world. Before the end of September 2020, nearly 32 million cases worldwide were recorded, with a death toll of approximately 1 million cases. As COVID-19 has spread across the world, certain groups of people prove more susceptible than others. Elderly patients and people with chronic medical conditions such as heart disease or diabetes are more likely to experience or even suffer from serious diseases. As a population, senior citizens take more medicines than young people. Similarly, people with chronic illnesses who are several taking drugs to control their illness. All this poses a significant query in managing COVID-19 cases: can a standard drug regimen be paired with one or more experimental drugs? For example, some of the most widely prescribed medicines—including antibacterial drugs, antifungals, heart-related medications, neuroleptics, contraceptives, and sedatives —can have extensive and often even severe interactions with some of the experimental COVID-19 therapy. Therefore, to reduce the morbidity and mortality rate associated with COVID-19, this issue needs to be answered in detail. This review addressed the key points related to the drug-drug and drug-disease interaction in patients with COVID-19. To help health care providers locate the answers they need in the shortest possible time, the information contained in this review has been included in easy-to-read tables. Keywords: Drug interactions; DDIs; Polypharmacy; SARS-CoV-2; COVID-19.


  • Open Access

    Multiple Unite Pellet Systems (MUPS) as Drug Delivery model

    byĀ Saad M. Majeed, Mohammed K. Al-Shaheen, Radhwan Nidal Al-Zidan, Sameer M. Mahmood

    Multiparticulate drug delivery systems are mainly oral dosage form, consist of small discrete units that exhibit different characteristics especially in release pattern and drug bioavailability. These systems are represented by granules, pellets, microspheres, microcapsules, and minitablets. Pellets offer high flexibility in the design, formulation, and development of oral dosage forms such as sachet, suspension, capsule, and tablet. Multiparticulate tablets manufactured by compaction of multiple unite pellets is one of the latest and, yet, challenging technologies. Multiparticulate tablets combine the benefits of both a tablet and a pellet-filled capsule in one dosage form but their manufacturing experience many difficulties. The oral multiparticulate products consist of polymer-coated subunits or pellets, which are embedded in an inert excipients’ matrix, formulated to overcome the difficulty in administering capsules and improve the physicochemical stability of suspension and offer predictable release and uniform distribution in the gastro-intestinal tract compared to the plain tablet. This review discusses the advantages and drawbacks of MUPS, the properties of an ideal MUPS, various pharmaceutical applications of MUPS, the challenges and key variables that to be considered in the tableting process for successful production of MUPS Keywords: MUPSĀ®, Pellets, Multiparticulate tablets.


  • Open Access

    The public health dilemma of Self-Medication with Antibiotics: The undergraduate students of the College of Pharmacy in Mosul as an example

    byĀ Radhwan N. Al-Zidan, Ahmed S. Saadallah, Ghayth M Abdulrazzaq

    To evaluate the behaviour of Pharmacy College students as a representative sample of undergraduate students in terms of the use of antibiotics in Mosul city, Iraq. A questionnaire was adopted from previous studies with minor modifications to suit the current study sample and distributed to undergraduate students from all stages of the College of Pharmacy at the University of Mosul, in Nineveh province, north of Iraq. The study sample included 429 students. The results were statistically analyzed using GraphPad prism 7 and Excel 2013. the study showed that 51.28 % (n=220) of the participants practiced self-medication with antibiotics over the past 6 months. Retail pharmacies were the most common source for obtaining the antibiotics (87.4%), followed by the nurse clinics (7.9%), and lastly from the leftovers (4.7%). The main reasons for self-medication with antibiotics were the belief of having good knowledge about antibiotic use, followed by assuming that practicing self-medication with antibiotics would save time and money or due to inadequate improvement following proper medical consultation and lack of the nearby health care providers. The major diseases being treated was URTIs. The most used antibiotic for self-medication was Amoxicillin and to a lesser extent Azithromycin Amoxicillin/Clavulanic Acid and Cefixime. Undergraduate students included in this survey had inadequate knowledge concerning antibiotics and a high rate of self-medication. This study calls attention to the need for focused educational intervention and rigorous authoritarian and governmental ruling regarding the issue of inappropriate antibiotic use and sale in community pharmacies.